HSBC set a €96.00 ($111.63) target price on Merck KGaA (FRA:MRK) in a research report released on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
Several other analysts also recently weighed in on the company. UBS Group set a €99.00 ($115.12) price objective on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. DZ Bank restated a buy rating on shares of Merck KGaA in a report on Wednesday, August 14th. Barclays set a €82.00 ($95.35) price objective on Merck KGaA and gave the company a sell rating in a report on Wednesday, August 14th. Independent Research set a €102.00 ($118.60) price objective on Merck KGaA and gave the company a neutral rating in a report on Friday, August 9th. Finally, Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the company a neutral rating in a research note on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of €100.67 ($117.05).
MRK stock opened at €94.32 ($109.67) on Thursday. The business has a 50-day moving average price of €93.72 and a 200 day moving average price of €94.53. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: What is meant by holder of record?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.